Tirilazad

Drug Profile

Tirilazad

Alternative Names: Freedox; Tirilazad mesylate; U 74006A; U 74006F; U 74389F

Latest Information Update: 19 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Pregnatrienes
  • Mechanism of Action Lipid peroxidation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Subarachnoid haemorrhage
  • Discontinued Craniocerebral trauma; Ischaemic heart disorders; Kidney disorders; Spinal cord injuries; Stroke; Transplant rejection

Most Recent Events

  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
  • 05 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
  • 28 May 1999 Tirilazad has failed to gain recommendation for approval by the US FDA for the treatment of aneurysmal subarachnoid haemorrhage
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top